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In sickle cell disease transfusions improve blood ﬂow by reducing the proportion of red cells capable of forming sickle hemoglobin
polymer. This limits hemolysis and the endothelial damage that result from high proportions of sickle polymer-containing red
cells. Additionally, transfusions are used to increase blood oxygen carrying capacity in sickle cell patients with severe chronic
anemia or with severe anemic episodes. Transfusion is well-deﬁned as prophylaxis (stroke) and as therapy (acute chest syndrome
and stroke) for major complications of sickle cell disease and has been instituted, based on less conclusive data, for a range of
additional complications, such as priapism, vaso-occlusive crises, leg ulcers, pulmonary hypertension, and during complicated
pregnancies. The major and unavoidable complication of transfusions in sickle cell disease is iron overload. This paper provides an
overview of normal iron metabolism, iron overload in transfused patients with sickle cell disease, patterns of end organ damage,
diagnosis, treatment, and prevention of iron overload.
1.Introduction
T h eh u m a nb o d yh a sn oe ﬀective physiological mechanism
for excreting excess iron. Therefore, in conditions such as
sickle cell disease (SCD), where transfusions are frequently
indicated, exogenous iron can accumulate, circulate as non-
transferrin bound iron (NTBI), enter tissues, form reactive
oxygenspecies(ROS),andresultinendorgandamage.How-
ever, patients with SCD, compared with thalassemic patients,
despiteasimilartransfusionload,mayberelativelyprotected
from iron mediated cardiac and endocrine gland toxicity
[1]. In thalassemia, ineﬀective erythropoiesis contributes to
iron overload directly and by regulating other downstream
pathways. The unfolding pathophysiology of transfusional
iron toxicity in SCD, less well studied than in thalassemia,
will be discussed.
2. Normal Iron Metabolism
Iron homeostasis in humans is maintained by the strict
regulation of absorption based on body needs. 1mg (10%
of total dietary iron) is absorbed daily, predominantly in
the duodenum, and an equal amount is lost through feces,
urine, and sweat [2]. In normal physiological conditions,
iron deﬁciency and anemia increase iron absorption, while
iron overload decreases it [3].
Nonheme iron absorption is relatively well characterized.
Ferric(Fe3+)isreducedtoferrous(Fe2+)ironintheduodenal
enterocyte by a ferric reductase (DcytB). Fe2+ is transported
into the cell by the Divalent Metal Transporter (DMT-1),
located at the apical brush border. In the absence of iron
overload, some absorbed iron is stored in the enterocyte
as ferritin and the rest is transported across the basolateral
membrane by ferroportin, with the aid of the ferroxidase
hephaestin. In the circulation, iron is bound to transferrin
and transported to the liver and bone marrow. In the liver,
transferrin receptors 1 and 2 mediate the endocytosis of iron,
which is then stored as ferritin and released by a ferroportin-
mediated mechanism when bodily needs increase. In the
erythroid precursors, transferrin bound iron is taken up by
transferrin receptor 1 and utilized for erythropoiesis. During
red cell senescence, iron is released into macrophages in the
reticuloendothelial system (RES) and is stored as ferritin and
hemosiderin; again, egress of iron from the macrophage is
ferroportin dependent [4](Figure 1).2 Advances in Hematology
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Figure 1: Iron absorption and transport [4]. Reproduced with permission from MMS, and author. Copyright c  (2005) Massachusetts
Medical Society. All rights reserved.
The presence of ferroportin on the cell membrane is
regulated by hepcidin, a 25-amino acid peptide synthesized
by the liver that is the principal hormone involved in
regulating iron absorption [5]. Hepcidin acts by binding
to the ferroportin transporter, triggering its internalization
and degradation, thereby diminishing net circulating iron
by reducing iron absorption in the gut and increasing iron
sequestration in the RES. Anemia, hypoxia, and erythro-
poiesis decreasehepcidingeneexpression, therebystabilizing
ferroportin and increasing circulating iron available for ery-
thropoiesis [6]. In contrast, acute and chronic inﬂammation
increase hepcidin expression and ferroportin degradation
[7]. The paradoxical iron restriction seen in the anemia
of chronic inﬂammation is associated with increased RES
iron and results from a high-hepcidin state. Hemojuvelin,
also expressed in the liver, is believed to positively regulate
hepcidin production [8]. Matriptase 2, a recently identiﬁed
serine protease, appears to be a sensor of iron deﬁciency and
inhibitor of hepcidin [9] .T h e s ep e p t i d e sh e l pr e g u l a t ei r o n
absorption and maintain homeostasis.
Heme iron absorption is less clearly characterized. Heme
Carrier Protein 1 (HCP-1), believed to facilitate heme
iron uptake, has been recently identiﬁed on the duodenal
enterocyte brush border [10]. Heme iron taken up by this
transporter is broken down by a heme oxygenase in the
enterocyte into iron and protoporphyrin [11]. It is unclear
whether heme is completely degraded into iron in the
enterocyte and absorbed via ferroportin, or if intact heme is
also transported via other mechanisms. The Feline Leukemia
Virus subgroup C Receptor (FLVCR) appears to play such
a role in transporting heme from erythroid precursors
[12, 13].
3. Indications for Transfusionin SCD
Transfusion is a frequently employed therapy in SCD, but
its best-validated uses have been in preoperative prophylaxis,
treatment of acute chest syndrome (ACS) and prophylaxis,
and treatment of stroke [14–16].
Transfusions ﬁrst demonstrated their eﬀectiveness in
reducing recurrent strokes in SCD [14, 17]. Subsequently,
transfusions have also proved to be eﬀective prophylaxis
against ﬁrst stroke in high risk patients. The Stroke Pre-
vention Trial in SCD (STOP) randomized 130 high-risk
children with SCD to either transfusion therapy (to maintain
HbS <30%) or observation [18]. These high risk children
had an increased blood ﬂow in the Internal Carotid or
Middle Cerebral Artery by Transcranial Doppler (TCD).
This study showed a 92% reduction in incidence of ﬁrst
stroke in transfused high-risk patients. A follow-up study,
STOP2,randomized 72childrenwhoseTCDhadnormalized
after 30 months of transfusion therapy to either ongoing or
discontinued transfusions. The study washalted prematurely
when a signiﬁcant increase in abnormal TCD velocity andAdvances in Hematology 3
stroke risk was seen in the group in which transfusion
therapy had been halted [19]. The optimal duration of
transfusion in SCD patients at high risk for primary or
recurrent stroke is still undeﬁned, resulting in long-term
transfusion management of a young population.
In addition to preventing strokes, transfusion is ben-
eﬁcial in other complications of SCD such as ACS [20,
21]. Vichinsky et al. showed that transfusion improves
oxygenation in ACS [22]. Subset analysis from the STOP
trial also showed a signiﬁcant reduction in the frequency
of ACS and painful crises in the transfused group [23]. In
addition, preemptive transfusion therapy was eﬀective in
preventing ACS in a small number of SCD patients with
elevated plasma secretory phospholipase A2 levels, an early
sign of ACS [24]. In a study of pregnant women (n = 72)
with SCD randomized to receive prophylactic transfusions
or transfusions for medical and obstetric emergencies only,
a signiﬁcant reduction in pain crises was observed in the
arm that received prophylactic transfusions [25]. Finally,
preoperative simple transfusion to maintain a hemoglobin
of 10gm/dL reduces peri- and postoperative complications
in patients with SCD [26–28].
4. Mechanism of Transfusion Mediated
Iron Overload
While transfusion may improve disease complications, iron
overload is a dreaded and inevitable consequence of ongoing
transfusion therapy. Chronically transfused iron overloaded
patients with SCD have signiﬁcantly higher mortality than
less transfused counterparts without iron overload, as well
as age and race-matched normal controls [29, 30]. This
ﬁnding may reﬂect disease severity rather than iron burden;
nonetheless, patients with SCD are far less likely to be
screened for end organ damage than patients with tha-
lassemia,despiteasimilartransfusionhistory[31].Therefore
knowledge of iron toxicity in SCD is of paramount impor-
tance.
T r a n s f u s i o no fp a c k e dr e db l o o dc e l l s( R B C s )p r o v i d e s
1mg per mL transfused of additional elemental iron. Long-
termtransfusiontherapyof,forinstance,20-unitsRBCs/year
is associated with signiﬁcant iron overload (20 units ×
220mL per unit × 1mg per mL = 4400mgm exogenous
iron/year) [32]. With repeated transfusions, serum trans-
ferrin becomes saturated and the excess circulating iron is
transport edasNTBI[33].NTBIenterscellsinadysregulated
fashion; a subset of NTBI, called Labile Plasma Iron (LPI),
may cause end organ damage secondary to its high redox
potential [34].
5.EndOrganToxicitydueto
Iron Overload in SCD
Saturation of transferrin by excess circulating iron results
in increased NTBI and LPI [35]. NTBI can appear in the
absence of transferrin saturation, the mechanism of which
is not yet clear [36]. NTBI and LPI tend to enter tissues
more readily and result in formation of reactive oxygen
Repeated transfusions resulting in
increased circulating iron
Increased saturation of transferrin
I n c r e a s e dN T B Ia n dL P I
NTBI and LPI enter tissues and form ROS causing
lipid peroxidation and end organ damage
Figure 2: Mechanism of end organ damage in iron overload.
species (ROS) such as the hydroxyl radical by the Haber
Weiss reaction [37, 38]. Excess iron tends to deposit in the
hepatic parenchyma, in endocrine organs, and in cardiac
myocytes, causing end organ damage by ROS-mediated lipid
peroxidation [39, 40] (Figure 2).
In patients with β thalassemia major (TM), long-term
transfusion causes iron overload that results in cardiac
damage, liver ﬁbrosis, gonadal dysfunction, and growth
retardation. Cardiac iron overload still remains the main
cause of mortality in TM despite chelation therapy [41].
Although large studies looking at long-term transfusion
and iron overload in SCD are lacking, available data suggest
that SCD patients are relatively protected from iron-induced
cardiac and endocrine organ damage as compared with TM
patients. In a study by Wood et al. comparing 19 patients
with TM and 17 patients with SCD (matched for age, sex,
transfusion duration, chelation therapy, and hepatic iron
content), cardiac iron overload, measured by T2∗MRI, and
cardiac dysfunction were signiﬁcantly more prevalent in the
g r o u pw i t hT M[ 42]. In another study, cardiac disease and
gonadal dysfunction seen in TM were not present in SCD
patientswithsimilarserumferritinlevelsandequivalentliver
iron content. Hepatic ﬁbrosis was detectable pathologically,
albeit at 39% in SCD (n = 43) compared with 81% in TM
(n = 30). TM patients had a signiﬁcantly longer duration
of transfusions and higher incidence of viral hepatitis in this
study [43].
Studies comparing the sequelae of iron overload in TM
versus SCD are of interest, but one must be cautious in
applying conclusions from these studies given the many
diﬀerences between TM and SCD patients clinically. These
reports highlight the need for independent study of the
contribution of iron overload to the morbidity and mortality
in SCD.
6.PotentialFactorsModifying
Iron Toxicity in SCD
The possible diﬀerence in iron mediated toxicity between
TM and SCD underscores the complexity of iron regulation.
Damage from iron overload is not merely a function of the
absolute amount of excess iron present. Modifying factors
include, but are not limited to, relative distribution of iron
loading in RES versus parenchymal cells, levels of NTBI4 Advances in Hematology
and LPI, coexisting hereditary iron loading defects, and the
impact of ineﬀective erythropoiesis.
The levels of NTBI and LPI, the most redox reactive
and toxic iron species, have been compared between SCD
and TM. In a small study, NTBI levels in SCD were less
than half of those seen in TM, despite higher ferritin levels
and hepatic iron concentration in SCD. However, patients
with thalassemia in this study had received 4 times more
transfusionthanthosewithSCD[44].Korenstudiedpatients
with SCD including HbSS and Sβ◦ thalassemia (n = 36) and
β Thalassemia, including TM and Thalassemia intermedia
(n = 43). The two groups overall were matched for
t r a n s f u s i o nl o a d( S C D :1 0 4± 77 and β Thalassemia 179 ±
103cc/kg/yr). In subset analyses, however, TM patients had
a signiﬁcantly greater transfusion burden than patients with
HbSS, which may account for signiﬁcantly lower NTBI and
LPI observed in SCD patients in this study. While only 1
patient with SCD developed cardiomyopathy, 32 patients
with TM had evidence of either cardiac or gonadal damage
[45].
Coexistenthereditaryironoverloadconditionshavebeen
studied in the context of SCD and the iron overload phe-
notype.Currentlydeﬁnedhemochromatosispolymorphisms
of European origin are less frequent in African Americans
and do not seem to contribute to exacerbated iron loading in
African Americans with SCD [46]. Nonetheless, other causes
of primary and dietary iron overload are well described
in populations of African descent, even if the underlying
genetics are not, and these may contribute to phenotypic
diversity in SCD and iron overload [47, 48].
The role of hepcidin in the pathophysiology of iron
overload in SCD remains controversial. Patients with SCD
suﬀer from recurrent infections and ongoing endothelial
damage by reperfusion injury that result in a chronic-
inﬂammatory-like state [49]. This is evidenced by increased
CRP,IFNγ, IL-1, and IL-6 in steady state and IL-6 and TNF-α
increaseduringcrises[50,51].Byanalogywiththeanemiaof
chronic inﬂammation (in which cytokines increase hepcidin
levels), one may speculate that hepcidin levels would be
elevated in SCD. However, hepcidin levels in nontransfused
steady-state SCD (n = 40) are not elevated when compared
withnormalcontrols(n = 30),evenwhenSCDpatientswith
infectionsandendorgandamagewereassessedasasubgroup
[52]. Another study, comparing hepcidin in 16 patients with
sickle syndromes (HbSS, HbSβ◦ thalassemia, HbSC) against
race matched controls heterozygous for HbS or HbC, also
found no diﬀerence among the groups. In fact, in 5 patients
with SCD in this study, hepcidin levels were below the
lower limit of normal, which was attributed to increased
erythropoietic activity [53]. Coexistent iron deﬁciency can
also aﬀect hepcidin estimation. Iron deﬁciency anemia has
been described in the pediatric population with SCD, both
due to nutritional status and intravascular hemolysis with
urinary iron losses. In a study of 70 children with HbSS and
HbSC,9%ofnontransfusedchildrenwerefoundtohaveiron
deﬁciency [54].
Although steady-state SCD patients do not exhibit
increased hepcidin levels, transfusion acutely up regulates
hepcidin mRNA expression [55]. It is unclear whether this
increased gene expression results in increased circulating
hepcidin and decreased unbound iron immediately post
transfusion. Nor is it known whether this transient increase
in hepcidin expression is of clinical relevance.
In contrast, hepcidin is signiﬁcantly downregulated in
patients with ineﬀective erythropoiesis such as thalassemia,
thereby worsening unbound iron toxicity in this population
[56–58]. Depressed urinary hepcidin levels relative to iron
burden have been associated with augmented but ineﬀective
erythropoiesis (thalassemia, congenital dyserythropoietic
anemia and sideroblastic anemia). This is in distinction to
conditions with augmented but eﬀective erythropoiesis, as
in hemolysis (hereditary spherocytosis, and autoimmune
hemolytic anemias), in which urinary hepcidin levels rel-
ative to iron burden are not signiﬁcantly depressed [59].
Hepcidin suppression in thalassemia may be mediated in
part by growth diﬀerentiation factor 15 (GDF-15). GDF-
15, a member of the TGF-β superfamily, is produced by
erythroid progenitors and reaches measurable serum levels
in the presence of ineﬀective erythropoiesis. GDF-15 levels
a r ee l e v a t e di nT M ,b u tn o ti nS C D .S e r u mf r o mT M
patients suppresses hepcidin expression in vitro, unless
GDF-15 is blocked [60]. Twisted gastrulation (TWSG1), a
cytokine produced during early stages of erythropoiesis, also
downregulateshepcidinandishighlyexpressedinthespleen,
bone marrow, and liver of thalassemic mice. The role of
TWSG1 in SCD has not been studied yet [61]. Hepcidin and
other cytokines (such as GDF 15 and TWSG1) are likely to
b ek e yt oo b s e r v e di r o nr e g u l a t i o ni nS C D .
7. Measurement of Iron Overload
The gold standard for assessing liver iron stores in the
absence of cirrhosis is the hepatic iron content (HIC),
determined by liver biopsy and quantitation with atomic
absorption spectrophotometry [62]. The normal HIC is
between 0.4 and 2.2mg/g of liver dry weight. Based on
data from hereditary hemochromatosis, <7mg/g is not
associated with obvious hepatic pathology while >15mg/g
is consistently associated with liver ﬁbrosis [63]. The use of
biopsy-measured HIC as a marker of iron overload is limited
by the small but ﬁnite risk of complications of liver biopsy,
lack of reproducibility of quantitative assays, and sampling
error [64].
Noninvasive methods including blood tests (ferritin
and iron saturation) and imaging techniques (MRI-based
techniques) have been evaluated as predictors of HIC.
Ferritin has been shown to correlate with HIC in TM,
but the correlation in SCD is less clear [65]. In a cross-
sectional study of 27 children with SCD who had received
chronic transfusion therapy without chelation, transfusion
volumecorrelatedwithhepaticironcontent(HIC)but,when
adjusted for transfusion volume, serum markers did not
[66]. In another study of 20 patients with SCD undergoing
chronictransfusiontherapywithironchelation,HICshowed
a positive correlation with the duration of transfusion and
liver ﬁbrosis but not with serum markers [67]. Analyses of
chronically transfused SCD patients without viral hepatitis
from the STOP and STOP2 trials, most of whom were onAdvances in Hematology 5
Table 1: Tests to estimate iron load.
TEST Application
Serum ferritin
Relatively unreliable in SCD, especially in the
range of 1500–3000ng/mL. In this range, levels
of ferritin do not linearly correlate with HIC
SQUID
Reliable predictor of HIC, but expensive and
available in few institutions worldwide, mostly
for research purposes
T2∗ MRI Well-validated predictor of HIC and cardiac
complications from iron overload
Liver biopsy
Gold standard. Accurate estimation of iron
overload except in ﬁbrosis. Invasive but <1%
risk of complications. Sampling error possible
chelation therapy, showed that a ferritin level <1500ng/mL
was correlated with low transfusion burden and low mea-
sured HIC, while a ferritin >3000ng/mL was consistently
predictive of HIC >10mg/g. The intermediate levels did not
correlate linearly with iron overload [68]. These data suggest
that serum ferritin may not be an accurate predictor of liver
iron stores, especially in the range of 1500 to 3000ng/mL.
Imaging techniques for noninvasive determination of
HIC have been developed and validated. The Superconduct-
ing Quantum Interference Device (SQUID) quantitatively
determines HIC by magnetic measurement, and in cases
of hereditary and transfusional iron overload has shown
signiﬁcant correlation with HIC as measured by biopsy [69].
However, this device is expensive and not readily available.
T2∗ MRI has been validated as a reliable noninvasive means
to assess iron stores in the liver and heart [70]. Increasing
iron content in the liver and heart reduces relaxation times
as measured by T1, T2, and T2∗ MRI. T2∗ values of
<20milliseconds in nonﬁbrotic livers correlates (r = 0.93)
with increased HIC by biopsy [71]. Similarly, cardiac T2∗
values of <20ms correlate with a decline in left ventricular
ejection fraction values, increase in cardiac arrhythmias, and
need for cardiac medications [72]. The reciprocal of this
relaxation time, R2 and R2∗, has also demonstrated good
direct correlation with HIC in patients with SCD [73]. From
these data it appears that MRI is a good noninvasive tool to
assess iron overload (Table 1).
8. Therapy for Transfusional
Iron Overload in SCD
8.1. Non Pharmacological Therapy. Decreasing transfusion
requirement by substituting erythracytapharesis for simple
transfusion, transfusing younger red cells, and performing
splenectomy in patients with hypersplenism have been
evaluated as nonpharmacological techniques for preventing
and treating iron overload. In erythrocytapharesis, patient
RBCs are removed as transfused blood is being infused. A
studywasperformedusingerythrocytapharesistoagoalHbS
of 50% in patients with history of stroke, recurrent VOC
or priapism, comparing them to historic controls treated
with simple transfusion or modiﬁed simple transfusions.
The degree of iron overload, as assessed by serum ferritin,
was signiﬁcantly reduced in 14 SCD patients treated by
erythrocytapharesis compare to those treated with simple
transfusion, in spite of an increased absolute requirement for
donor units [74]. This approach is hampered by practical
resource limitations at donor centers and by complications
of permanent vascular access in SCD [75, 76]. Furthermore,
increased exposure to donor units also raises the risk of
alloimmunization to further deter its wider acceptance in the
community [77].
Transfusion of young erythrocytes called neocytes sig-
niﬁcantly reduces transfusion requirements and prolongs
transfusion interval by 15–25%. However, this occurs at the
expense of increased donor exposure and costs [78], and this
technique is not widely used.
Retrospective analysis of 34 pediatric patients with
SCD (HbSS, HbSC, HbSβ◦ thal) for 6 months before and
12 months after splenectomy for splenic sequestration or
hypersplenism showed a signiﬁcant reduction in transfusion
requirements postsplenectomy [79]. Splenectomy, however,
isassociatedwithlong-termrisk of infectionbyencapsulated
organisms and likely beneﬁts few adult patients with SCD
since autosplenectomy commonly leaves them without a
functioning spleen.
8.2. Pharmacological Therapy. Chelation therapy is routinely
employed to prevent and treat iron overload in chronically
transfused SCD patients. Chelators work by targeting the
unbound iron in the blood, including NTBI and LPI that
cause tissue injury [80]. Diﬀerent parameters have been used
toestimateironloadanddetermineneedforchelation.These
include HIC by liver biopsy, serum markers such as ferritin,
and transfusional iron load (TIL).
8.2.1. Indications to Commence Chelation Therapy. Tradi-
tionally, determining HIC by liver biopsy is considered
the gold standard to predict iron overload and determine
need for chelation therapy. Based on data from hereditary
hemochromatosis and TM showing that elevated HIC over
7mg/g liver dry weight is a risk factor for hepatic ﬁbrosis,
this value has been used as a guide to start chelation [63, 81].
In a study of 12 pediatric patients with SCD who previously
received an average of 15 transfusions over 21 months, mean
HIC was 9.4 ± 1.2mg/g dry weight, and 4 of 12 patients had
liver ﬁbrosis, validating that a cut oﬀ of 7mg/g could be used
as a guide for SCD as well [82]. Vichinsky et al. described 43
adult patients with SCD who were previously transfused for
a mean of 6 years, resulting in elevated ferritin levels at 2916
± 233ng/mL, and increased HIC, at 14.33 ± 1.4mg/g dry
weight. Only 2% of these SCD patients had viral hepatitis,
but 39% of them had an elevated ﬁbrosis score at liver biopsy
suggesting that adults with SCD have a similar response to
iron overload [43].
As mentioned previously, noninvasive estimates of HIC
are less predictive of the need for liver biopsy and possible
therapy for iron overload. Serum ferritin of >1000ng/mL,
used as a guide in patients with thalassemia, is not validated
in SCD. While in SCD ferritin levels of over 3000ng/mL
are associated with HIC >10mg/g, values between 1500
and 3000ng/mL are not predictive of an elevated HIC6 Advances in Hematology
Table 2: Indications for chelation therapy in SCD.
Test Adult patients Pediatric patients
Transfusional iron load 20 to 30 units >100mg/kg
Serum ferritin >3000ng/mL, 1500–3000ng/mL: equivocal >3000ng/mL, 1500–3000ng/mL: equivocal
HIC >7–9mg/g dry weight >7–9mg/g dry weight
[67]. A better parameter for noninvasive estimation is
transfusional iron load (TIL). TIL of >100mg/kg has been
closely correlated with high liver iron stores and liver ﬁbrosis
in the pediatric population and is an indication to start
chelation therapy [65, 67]( T a b l e2). There are no systematic
studies in adults with SCD. 30 units of RBCs in a 70Kg
adult would result in 94mg/Kg iron load, and so ﬁndings
in children with SCD are congruent with recommendations
for secondary iron overload in myelodysplastic syndrome
in adults, where chelation is suggested after transfusion
of 20–30 units of packed RBCs, or a ferritin of
>2500ng/mL [83] (see National Cancer Comprehensive
Network Clinical Practice Guidelines in Oncology v.2.2010)
(http://www.nccn.org/professionals/physician gls/PDF/mds
.pdf).
8.2.2. Chelating Agents. Deferoxamine (DFO), the ﬁrst iron
chelatorintroducedinthe1970s,isderivedfromthemicrobe
Streptomyces pilosus. Due to poor oral absorption it is
administered parenterally. In the liver it is converted to active
metabolites that chelate-free iron and eliminate it through
urine and feces. Only 10% of the administered drug is
available for chelation [84]. Although initially given intra-
muscularly, therapy was later optimized as subcutaneous
infusions of 30–50mg/kg for 8–12 hours every night for 5–7
nights per week [41]. Dose adjustment is performed based
on ferritin to DFO ratio. With good compliance the drug
prevents and reverses cardiac dysfunction and signiﬁcantly
improves survival [85]. Adverse eﬀects include reversible
sensorineural hearing loss, retinal damage, and growth
retardation [86]. Yearly audiologic and ophthalmologic
e v a l u a t i o n sa r ea d v i s e ds i n c ee a r l ye ﬀects are reversible. Rare
cases of renal failure and interstitial pneumonitis have also
been reported.
However, continuous parenteral administration makes
DFO less attractive, and compliance is poor [87, 88].
Children and adults with thalassemia have been treated with
subcutaneous DFO injections every twelve hours as a more
acceptable alternative to continuous infusions, though the
amount of drug that can be administered by bolus injections
is limited [89, 90].
Oral alternatives include Deferasirox (DFS) and
Deferiprone (DFP). DFS is an FDA approved oral iron
chelator. In a randomized open label multicenter phase
II study, one year of DFS therapy was compared against
DFO in chronically transfused SCD and both drugs were
found to be equally eﬃcacious. Side eﬀect proﬁle of DFS
was similar to DFO including >10% headache, skin rash,
and gastrointestinal toxicity as well as less common hearing
and visual side eﬀects [91]. Renal toxicity has been described
in DFS, and the target dose for eﬃcacy is approximately
25–30mg/Kg. Compliance is variable because of taste, and
DFS, like DFO, is expensive.
Deferiprone is an oral iron chelator licensed for use
in Europe. Safety of this drug was demonstrated in a
multicenter prospective study but long-term data regarding
eﬃcacy is lacking. It appears to have the greatest eﬃcacy
in chelating cardiac iron but, because of early controversial
studies in North America, is not licensed for use by the FDA
[92, 93].
The eﬃcacy and safety of combination therapy using
diﬀerent chelators is also being studied.
9. Conclusion
Iron overload is a feared complication of long-term transfu-
sioninSCD.TheindicationsfortransfusioninSCDcontinue
to broaden and minimizing unnecessary transfusions in
patients with SCD should be strongly emphasized in the
clinical setting to reduce complications of iron overload.
Optimum use of nontransfusion therapy such as Hydrox-
yurea may mitigate some, but not all need for transfusion
therapy. Whether nonmyeloablative bone marrow trans-
plantation replaces long-term transfusion therapy in some
situations remains to be seen. SCD patients may be relatively
protected from end organ damage due to iron toxicity, for
reasons incompletely understood. Hepcidin is likely central
to diﬀerences observed between iron toxicity in SCD and in
thalassemia.
In SCD, a condition with a strong inﬂammatory com-
ponent, ferritin, which is an acute-phase reactant, may
not accurately predict body iron stores. Based on currently
available data (often extrapolated from other diseases),
chelation therapy should be considered when:
(1) adult patients with SCD have received 20–30 units of
RBC transfusions,
(2) pediatric patients with SCD are approaching a TIL ≥
100 mg/Kg, and/or
(3) HIC in any age group exceeds 7–9mg/g
(a) Excessive HIC is likely when the serum ferritin
is >3000ng/mL, less clear at 1500–3000ng/mL.
Oral and parenteral chelators with a range of side
eﬀects and costs are now available that can be tailored
to individual patients; nonetheless, simple and inexpensive
chelation remains an elusive goal.
Challenges remain in the prevention and management
of iron overload in SCD. Increased federal research support
would beneﬁt clinical investigation into practical matters
suchasclariﬁcationoftheindicationsfortransfusiontherapyAdvances in Hematology 7
in adults with SCD, improved catheter technology to allow
safe exchange transfusions, and optimal chelation therapy.
Important unaddressed pathophysiologic questions include
the etiology of nonhepatic risks of iron overload in adults
(such as pulmonary hypertension, the risk for which has
been correlated with ferritin levels), and a more complete
elucidation of the role that perturbed iron absorption,
transport, and storage play in damage from iron overload in
SCD.
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